Recent Finacing
Recent Raise
Cleara Biotech develops FOXO4-based D‑amino acid peptide therapies targeting scarred-cell senescence for late-stage cancers and chronic diseases, advancing two preclinical candidates with organoid and mouse efficacy.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
See the team members at Cleara Biotech.
